Redeye sees the end-of-year report as results as uneventful. More important were the indications of a good start to the Swedish launch, the conclusion of the enrollment to the Phase 3 study, and progress regarding the Terbinafine supply. These factors are essential next steps for Moberg Pharma’s commercialization of MOB-015. The national approvals in the remaining countries in the DCP process are in process and will be approved.